Brooklands Fund Management Ltd Invests $1.54 Million in MaxCyte, Inc. $MXCT

Brooklands Fund Management Ltd acquired a new position in MaxCyte, Inc. (NASDAQ:MXCT) during the 1st quarter, HoldingsChannel.com reports. The firm acquired 2,190,020 shares of the company’s stock, valued at approximately $1,538,000. MaxCyte accounts for about 1.7% of Brooklands Fund Management Ltd’s investment portfolio, making the stock its 17th biggest holding.

A number of other institutional investors and hedge funds have also bought and sold shares of MXCT. AQR Capital Management LLC lifted its position in MaxCyte by 227.3% during the first quarter. AQR Capital Management LLC now owns 95,501 shares of the company’s stock valued at $261,000 after purchasing an additional 66,323 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of MaxCyte by 10.6% in the 2nd quarter. American Century Companies Inc. now owns 196,686 shares of the company’s stock worth $429,000 after buying an additional 18,848 shares during the last quarter. Prudential Financial Inc. purchased a new stake in shares of MaxCyte during the 2nd quarter valued at $26,000. Hsbc Holdings PLC raised its position in shares of MaxCyte by 410.2% during the 2nd quarter. Hsbc Holdings PLC now owns 273,218 shares of the company’s stock valued at $598,000 after buying an additional 219,662 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of MaxCyte during the 2nd quarter worth $282,000. 68.81% of the stock is owned by hedge funds and other institutional investors.

MaxCyte Price Performance

Shares of NASDAQ MXCT opened at $1.12 on Friday. MaxCyte, Inc. has a one year low of $0.64 and a one year high of $2.33. The firm’s 50 day simple moving average is $1.19 and its two-hundred day simple moving average is $1.00. The stock has a market capitalization of $119.97 million, a P/E ratio of -3.03 and a beta of 1.47.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.06. MaxCyte had a negative net margin of 121.16% and a negative return on equity of 20.03%. The firm had revenue of $6.22 million during the quarter, compared to analyst estimates of $7.28 million. As a group, equities analysts expect that MaxCyte, Inc. will post -0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MXCT has been the topic of a number of research analyst reports. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings lowered MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 10th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.00.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.